Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities

Alzheimer's and Dementia

Volumn 9, Issue 5 SUPPL., 2013, Pages

  Zago, Wagner ^a   Schroeter, Sally ^a   Guido, Teresa ^a   Khan, Karen ^a   Seubert, Peter ^a   Yednock, Ted ^a   Schenk, Dale ^a   Gregg, Keith M ^a   Games, Dora ^a   Bard, Frédérique ^a   Kinney, Gene G ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

ARIA; Immunotherapy; Microhemorrhage; Vascular amyloid

Indexed keywords

3D6 ANTIBODY; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; BAPINEUZUMAB; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; AQP4 PROTEIN, MOUSE; AQUAPORIN 4; COLLAGEN TYPE 4; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CAPILLARY; BRAIN HEMORRHAGE; CONTROLLED STUDY; IMMUNOTHERAPY; LOADING DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BLOOD VESSEL; BRAIN; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INTRACRANIAL HEMORRHAGES; MENINX; METABOLISM; MUTATION; PATHOLOGY; TIME FACTOR; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUAPORIN 4; BLOOD VESSELS; BRAIN; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL HEMORRHAGES; MENINGES; MICE; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MUTATION; TIME FACTORS;

EID: 84885595750     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.11.010     Document Type: Article

References (39)

1. B.T. Hyman New neuropathological criteria for Alzheimer disease Arch Neurol 55 1998 1174 1176
2. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol 9 2010 702 716
3. D. Schenk, D. Games, and P. Seubert Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization J Mol Neurosci 17 2001 259 267
4. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, and H. Grajeda Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 6 2000 916 919
5. D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, and T. Guido Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
6. J.O. Rinne, D.J. Brooks, M.N. Rossor, N.C. Fox, R. Bullock, and W.E. Klunk 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study Lancet Neurol 9 2010 363 372
7. Sperling R. A randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with Alzheimer's disease who are apolipoprotein E ε4 carriers. 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden, 2012.
8. R.S. Black, R.A. Sperling, B. Safirstein, R.N. Motter, A. Pallay, and A. Nichols A single ascending dose study of bapineuzumab in patients with Alzheimer disease Alzheimer Dis Assoc Disord 24 2010 198 203
9. S. Salloway, R. Sperling, S. Gilman, N.C. Fox, K. Blennow, and M. Raskind A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 73 2009 2061 2070
10. C. Carlson, W. Estergard, J. Oh, J. Suhy, C.R. Jack Jr., and E. Siemers Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab Alzheimers Dement 7 2011 396 401
11. R.P. Kloppenborg, E. Richard, M.E. Sprengers, D. Troost, P. Eikelenboom, and P.J. Nederkoorn Steroid responsive encephalopathy in cerebral amyloid angiopathy: a case report and review of evidence for immunosuppressive treatment J Neuroinflammation 7 2010 18
12. R. Sperling, R. Bronen, S.M. Greenberg, G. Sorensen, S. Salloway, and A. Gass Three cases of apparent vasogenic edema (VE) from a phase 2 clinical trial of the gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate AD Alzheimers Dement 7 2011 S377
13. S. Ostrowitzki, D. Deptula, L. Thurfjell, F. Barkhof, B. Bohrmann, and D.J. Brooks Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab Arch Neurol 69 2012 198 207
14. R. Sperling, S. Salloway, D.J. Brooks, D. Tampieri, J. Barakos, and N.C. Fox Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 11 2012 241 249
15. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, and B.T. Hyman Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 7 2011 367 385
16. F. Panza, V. Frisardi, B.P. Imbimbo, D. Seripa, F. Paris, and A. Santamato Anti-beta-amyloid immunotherapy for Alzheimer's disease: focus on bapineuzumab Curr Alzheimer Res 8 2011 808 817
17. W. Zago, M. Buttini, T.A. Comery, C. Nishioka, S.J. Gardai, and P. Seubert Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific J Neurosci 32 2012 2696 2702
18. S. Schroeter, K. Khan, R. Barbour, M. Doan, M. Chen, and T. Guido Immunotherapy reduces vascular amyloid-beta in PDAPP mice J Neurosci 28 2008 6787 6793
19. P. Seubert, R. Barbour, K. Khan, R. Motter, P. Tang, and D. Kholodenko Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse Neurodegener Dis 5 2008 65 71
20. L.G. Luna Methods for pigments and minerals Manual of histological staining methods of the Armed Forces Institute of Pathology 3rd ed. 1968 McGraw-Hill Book Co. New York 174 188
21. D.M. Wilcock, A. Rojiani, A. Rosenthal, S. Subbarao, M.J. Freeman, and M.N. Gordon Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage J Neuroinflammation 1 2004 24
22. G.J. Burbach, A. Vlachos, E. Ghebremedhin, D. Del Turco, J. Coomaraswamy, and M. Staufenbiel Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage Neurobiol Aging 28 2007 202 212
23. D.R. Thal, W.S. Griffin, R.A. de Vos, and E. Ghebremedhin Cerebral amyloid angiopathy and its relationship to Alzheimer's disease Acta Neuropathol 115 2008 599 609
24. D. Boche, E. Zotova, R.O. Weller, S. Love, J.W. Neal, and R.M. Pickering Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain Brain 131 2008 3299 3310
25. M.C. Papadopoulos, G.T. Manley, S. Krishna, and A.S. Verkman Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema FASEB J 18 2004 1291 1293
26. D.M. Wilcock, M.P. Vitek, and C.A. Colton Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease Neuroscience 159 2009 1055 1069
27. J. Yang, L.K. Lunde, P. Nuntagij, T. Oguchi, L.M. Camassa, and L.N. Nilsson Loss of astrocyte polarization in the tg-ArcSwe mouse model of Alzheimer's disease J Alzheimers Dis 27 2011 711 722
28. J. Attems, H. Yamaguchi, T.C. Saido, and D.R. Thal Capillary CAA and perivascular Abeta-deposition: two distinct features of Alzheimer's disease pathology J Neurol Sci 299 2010 155 162
29. D.M. Wilcock, and C.A. Colton Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice CNS Neurol Disord Drug Targets 8 2009 50 64
30. M.M. Racke, L.I. Boone, D.L. Hepburn, M. Parsadainian, M.T. Bryan, and D.K. Ness Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta J Neurosci 25 2005 629 636
31. M. Rigol, N. Solanes, M. Roque, J. Farre, M. Batlle, and S. Roura Hemosiderin deposits confounds tracking of iron-oxide-labeled stem cells: an experimental study Transplant Proc 40 2008 3619 3622
32. C. Cordonnier, and W.M. van der Flier Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 134 2011 335 344
33. A. Biffi, and S.M. Greenberg Cerebral amyloid angiopathy: a systematic review J Clin Neurol 7 2011 1 9
34. Z. Nagy, M.M. Esiri, K.A. Jobst, C. Johnston, S. Litchfield, and E. Sim Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease Neuroscience 69 1995 757 761
35. D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, and S.H. Joo Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease Proc Natl Acad Sci U S A 90 1993 9649 9653
36. S.D. Preston, P.V. Steart, A. Wilkinson, J.A. Nicoll, and R.O. Weller Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain Neuropathol Appl Neurobiol 29 2003 106 117
37. R.O. Weller, M. Subash, S.D. Preston, I. Mazanti, and R.O. Carare Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease Brain Pathol 18 2008 253 266
38. R.O. Weller, S.D. Preston, M. Subash, and R.O. Carare Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease Alzheimers Res Ther 1 2009 6
39. E. Tarkowski, A.M. Liljeroth, L. Minthon, A. Tarkowski, A. Wallin, and K. Blennow Cerebral pattern of pro- and anti-inflammatory cytokines in dementias Brain Res Bull 61 2003 255 260